Compare VVPR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVPR | DTIL |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 123.0M |
| IPO Year | 2016 | 2019 |
| Metric | VVPR | DTIL |
|---|---|---|
| Price | $2.95 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | ★ 312.4K | 197.0K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,000.00 | ★ $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 281.25 | N/A |
| 52 Week Low | $0.62 | $3.61 |
| 52 Week High | $8.88 | $8.82 |
| Indicator | VVPR | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 41.67 |
| Support Level | $2.37 | $4.61 |
| Resistance Level | $2.78 | $5.20 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 70.53 | 35.68 |
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.